Literature DB >> 24392976

A regulatory perspective on essential considerations in design and analysis of subgroups when correctly classified.

Sue-Jane Wang1, H M James Hung.   

Abstract

This regulatory research provides possible approaches for improvement to conventional subgroup analysis in a fixed design setting. The interaction-to-overall effects ratio is recommended in the planning stage for potential predictors whose prevalence is at most 50% and its observed ratio is recommended in the analysis stage for proper subgroup interpretation if sample size is only planned to target the overall effect size. We illustrate using regulatory examples and underscore the importance of striving for balance between safety and efficacy when considering a regulatory recommendation of a label restricted to a subgroup. A set of decision rules gives guidance for rigorous subgroup-specific conclusions.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24392976     DOI: 10.1080/10543406.2013.856022

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  6 in total

Review 1.  Design, data monitoring, and analysis of clinical trials with co-primary endpoints: A review.

Authors:  Toshimitsu Hamasaki; Scott R Evans; Koko Asakura
Journal:  J Biopharm Stat       Date:  2017-10-30       Impact factor: 1.051

Review 2.  Clinical trial designs incorporating predictive biomarkers.

Authors:  Lindsay A Renfro; Himel Mallick; Ming-Wen An; Daniel J Sargent; Sumithra J Mandrekar
Journal:  Cancer Treat Rev       Date:  2016-01-05       Impact factor: 12.111

Review 3.  Subgroup analyses in confirmatory clinical trials: time to be specific about their purposes.

Authors:  Julien Tanniou; Ingeborg van der Tweel; Steven Teerenstra; Kit C B Roes
Journal:  BMC Med Res Methodol       Date:  2016-02-18       Impact factor: 4.615

Review 4.  Guidance from key organisations on exploring, confirming and interpreting subgroup effects of medical treatments: a scoping review.

Authors:  Stan R W Wijn; Maroeska M Rovers; Ly H Le; Michail Belias; Jeroen Hoogland; Joanna IntHout; Thomas Debray; Johannes B Reitsma
Journal:  BMJ Open       Date:  2019-08-24       Impact factor: 2.692

5.  Classification of Companion Diagnostics: A New Framework for Biomarker-Driven Patient Selection.

Authors:  Cynthia Huber; Tim Friede; Julia Stingl; Norbert Benda
Journal:  Ther Innov Regul Sci       Date:  2021-11-28       Impact factor: 1.778

6.  REFRESH protocol: a non-inferiority randomised clinical trial comparing internet and teleconference to in-person 'Managing Fatigue' interventions on the impact of fatigue among persons with multiple sclerosis.

Authors:  Matthew Plow; Tanya Packer; Virgil G Mathiowetz; Kathy Preissner; Setareh Ghahari; Abdus Sattar; Francois Bethoux; Marcia Finlayson
Journal:  BMJ Open       Date:  2020-08-16       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.